Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, noviembre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
MaxCyte Inc
MXCT
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.37
0.09
7.03%
al cierre: Nov 20, 4:00 PM EST
$1.29
-0.08
-5.84%
After hour: Nov 20, 6:47 AM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
MaxCyte Financials
MaxCyte (MXCT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
MaxCyte FY2026 Revenue expected to be more than $34.500M vs $32.211M Est
MaxCyte (NASDAQ:MXCT) FY2026 Revenue expected to be more than $34.500M vs $32.211M Est
Benzinga Newsdesk
PRO
MaxCyte Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $10.152M Beat $7.481M Estimate
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 58.33 percent increase over losses of $(0.12) per share from the same
Benzinga Newsdesk
PRO
MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M
MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
Benzinga Newsdesk
PRO
MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $31.082M Est
MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 million-$32.000 million vs $31.082 million estimate.
Benzinga Newsdesk
PRO
MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M Estimate
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 33.33 percent increase over losses of $(0.12) per share from the same
Benzinga Newsdesk
Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED)
(Editor’s note: The future prices of benchmark tracking ETFs, and the headline, the lede and the economic were updated in the story.) U.S. stock futures were mixed on Wednesday after Monday’s mostly lower close. Dow Jones futures fell, whereas S&P 500 and Nasdaq 100 indices were rising.
Rishabh Mishra